Bloomberg -- Sanofi-Aventis SA’s patents on its cancer drug Taxotere were ruled invalid by a U.S. judge, potentially clearing the way for Hospira Inc. and Apotex Inc. to start selling generic versions of the medicine.
Bloomberg -- Sanofi-Aventis SA’s patents on its cancer drug Taxotere were ruled invalid by a U.S. judge, potentially clearing the way for Hospira Inc. and Apotex Inc. to start selling generic versions of the medicine.
